FindTrial
Sign In

CLEAR FIBROSIS HEART TRAIL

Perfenidone in Endomyocardial Fibrosis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025735
Enrollment
108
Registered
2020-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I52- Other heart disorders in diseasesclassified elsewhere

Interventions

Intervention1: Perfenidone Drug: Start with 200 mg TDS orally , if tolerated after one week increase to 400 mg TDS and if tolerated increase to 600 mg TDS orally Control Intervention1: Placebo: Placeb

Sponsors

Rohit Walia
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Endomyocardial Fibrosis patients Informed consent

Exclusion criteria

Exclusion criteria: Chronic Renal Failure Liver Failure Expected life expectancy less than one year Associated Malignancy Assisted circulation Cardiac devices Contraindications to MRI

Design outcomes

Primary

MeasureTime frame
change in myocardial extracellular volumeTimepoint: 1 year—

Secondary

MeasureTime frame
Absolute change in LV and RV mass, volume, ejection fraction, myocardial cell volume, LV diastolic function, strain, backscatter and backscatter and torsion Absolute change in left atrium and right atrium volume and function and left atrial function , Absolute change in NT pro BNP and HS- Troponin T ,Absolute change in exercise tolerance All-cause mortality, cardiovascular mortality, hospitalisations due to heart failure and arrhythmias will be recorded Timepoint: 1 year—

Countries

India

Contacts

Public ContactRohit Walia

All India Institute of Medical Science , Rishikesh

rwalia7731@yahoo.in8800492549

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026